Ipsen Eyes Expanded Market for Cabometyx After Trial Success
Company Announcements

Ipsen Eyes Expanded Market for Cabometyx After Trial Success

Ipsen (FR:IPN) has released an update.

Ipsen has expanded its agreement with Exelixis, leveraging promising results from the CABINET Phase III trial to potentially market Cabometyx® for advanced neuroendocrine tumors in territories excluding the U.S. and Japan. The trial showed a significant improvement in progression-free survival for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. Ipsen is now in discussions with EU regulatory authorities to pursue marketing authorizations based on these clinical findings.

For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskIpsen Wins Second Shingo Prize for Excellence
TipRanks European Auto-Generated NewsdeskIpsen’s Kayfanda® Gets EU Approval for Rare Liver Disease
TipRanks European Auto-Generated NewsdeskIpsen’s New PBC Treatment Iqirvo Gains EU Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App